Additional close of $10 million USD brings total raised in Series A to $46 million USD
Funding co-led by Astellas Venture Management and Parkwalk Advisors with participation from other internal investors.
Funding will support advancement of Mogrify’s dedicated pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.
